DeanFBajorinMD

Genitourinary Oncology

Professor of Medicine, Weill Cornell Medical College

Overview of Dr. Bajorin

Dr. Dean Bajorin is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from New York Medical College and has been in practice 39 years. Dr. Bajorin accepts several types of health insurance, listed below. He is one of 497 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
353 East 68th Street
New York, NY 10065
Book by Phone+1(231) 674-7880

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1983 - 1986
University of ConnecticutResidency, Internal Medicine, 1978 - 1981
New York Medical CollegeClass of 1978

Certifications & Licensure

NY State Medical License 1985 - 2026
NJ State Medical License 2020 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2011-2014
Top Doctors: New York Metro Area Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2010-2013
Fellow (FASCO) American Society of Clinical Oncologists, 2011
New York Magazine: Top Doctors Castle Connolly, 2010
Fellow (FACP) American College of Physicians, 1999
Join now to see all

Clinical Trials

Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer Start of enrollment: 1995 May 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer Start of enrollment: 1996 Nov 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer Start of enrollment: 1997 Sep 01
Completed
Phase 1, Phase 2
Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer Start of enrollment: 1997 Sep 01
Completed
Phase 1
Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer Start of enrollment: 1997 Dec 01
Completed
Phase 1
Arsenic Trioxide in Treating Patients With Urothelial Cancer Start of enrollment: 2000 Dec 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Bladder Cancer Start of enrollment: 2004 Mar 01
Completed
Phase 3
Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas Start of enrollment: 2003 Oct 28
Completed
Phase 1
Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium Start of enrollment: 2006 Sep 01
Completed
Phase 2
Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment Start of enrollment: 2007 Mar 01
Completed
Phase 2
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma Start of enrollment: 2006 May 01
Completed
Phase 2
Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium Start of enrollment: 2008 Dec 05
Completed
Phase 2
Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer Start of enrollment: 2009 Feb 01
Completed
Phase 2
A Genotype-Phenotype Urothelial Cancer Registry Start of enrollment: 2009 May 01
Recruiting
A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies Start of enrollment: 2009 Dec 11
Completed
Phase 1
Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies Start of enrollment: 2010 Aug 01
Completed
Phase 1
Tesetaxel for Previously Treated Patients With Bladder Cancer Start of enrollment: 2010 Sep 01
Unknown status
Phase 2
RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder Start of enrollment: 2010 Dec 01
Completed
Phase 1, Phase 2
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma Start of enrollment: 2011 Jun 01
Terminated
Phase 2
Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium Start of enrollment: 2012 Mar 01
Completed
Phase 2
Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer Start of enrollment: 2012 Apr 01
Completed
Phase 2
Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy Start of enrollment: 2012 Jun 01
Terminated
Phase 2
Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer Start of enrollment: 2013 Aug 01
Terminated
Phase 2
Lenalidomide Maintenance in Plasma Cell Myeloma Start of enrollment: 2015 Aug 31
Active, not recruiting
Phase 2
Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)] Start of enrollment: 2018 Jun 27
Recruiting
Phase 2
Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11) Start of enrollment: 2018 Aug 01
Active, not recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

1 citations
Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274.
Matthew D Galsky, Johannes Alfred Witjes, Jürgen E Gschwend, Matthew I Milowsky, Michael Schenker
Journal of Clinical Oncology. 2025-01-01
1 citations
Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma With Prognostic Implications.
Dilara Akbulut, Karissa Whiting, Min-Yuen Teo, Jacob E Tallman, Gamze Gokturk Ozcan
Modern Pathology. 2024-10-01
2 citations
Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk Disease.
Jack P Gleeson, Andrea Knezevic, Maria Bromberg, Sujata Patil, Joel Sheinfeld
Journal of Clinical Oncology. 2024-09-10

Press Mentions

Immunotherapy After Bladder Cancer Surgery May Reduce Recurrence, Study ShowsJune 4th, 2021
Women Leaders at MSK: Diane Reidy-LagunesApril 2nd, 2021
Adjuvant Therapy for Improved Disease-Free Survival for Patients with Muscle-Invasive Urothelial Carcinoma Following Radical Surgery - Checkmate 274 - Petros GrivasMarch 28th, 2021
Join now to see all

Grant Support

Cancer Chemotherapy Training ProgramNational Cancer Institute2006–2011
Mskcc Clinical Research Methodology CurriculumNational Center For Research Resources2005–2007
Clinical Research Methodology CurriculumNational Heart, Lung, And Blood Institute1999–2004

Professional Memberships

American Society of Clinical Oncology - ASCO
Fellow
American College of Physicians - ACP
Fellow

Insurance Accepted

Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
Sagamore Health Plus
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment